Body Surface Area: Why 'How Much of You' Decides Your Treatment

The dullest number in the room decides which door you go through

Ask someone with psoriasis or eczema what their disease score is and you may get a PASI or an EASI. Ask what proportion of their skin is involved and you will usually get a shrug and a gesture. Yet that second figure — body surface area, the percentage of you that the disease is currently on — is doing more work in the clinical decision than almost anything else in the notes.

It sits at the boundary between topical and systemic therapy. It appears in the eligibility criteria of nearly every trial in inflammatory skin disease. It determines how much product a prescription needs to contain to be a real treatment rather than a gesture. And it is the number a reimbursement decision most often hangs on, which means getting it wrong has consequences that are administrative as well as clinical.

It is also estimated badly, consistently, and in one direction. In a classic comparison, four untrained observers using the rule of nines assessed the same ten patients with psoriasis and returned average extents of 20%, 14%, 23% and 33%. Image analysis of plaque tracings on those same patients gave 9%; whole-body photograph analysis gave 7%. The estimates were not scattered around the truth. They were all above it, some by a factor of four.

And this is not only a patient problem. When physician estimates were compared against computer-assisted image analysis, they were correct under half the time and skewed high, with the worst agreement in the middle of the range — precisely where the treatment decisions live.

The palm rule, and the detail nearly everyone gets wrong

The handiest measuring instrument for this is the one attached to your wrist, and the rule has a version that works and a version that doesn't.

The working version: a whole handprint — palm plus the fingers, held flat — approximates 1% of total body surface area. The version people actually use, the palm alone with fingers excluded, does not approximate 1%. It lands closer to half of that. The distinction was tested directly, and it matters enormously: swap one for the other and you have doubled or halved your estimate before you started counting.

A meta-analysis of hand and palm measurements added the corrections that make the rule honest. Hand surface area in adults runs about 13% below the assumed 1%, so the whole-hand rule over-estimates for adults and particularly for women. In children it does the opposite and under-estimates. The proportion falls as BMI rises, because body area grows faster than hands do. And when European, Chinese and Indian subcontinent groups were compared, each differed from the others. The palm-alone figure of half a percent, meanwhile, held up reasonably for adults.

None of this makes the palm rule useless. It makes it a rule with a stated error bar — which is more than can be said for the alternative, which is guessing. The rule of nines, by contrast, was designed for burns: large, contiguous, unambiguous areas of a limb or torso. Applied to inflammatory skin disease it fails for a structural reason, and that reason is the next section.

A scatter is not a sum

Burns cover regions. Psoriasis and eczema cover parts of regions, in patches, with unaffected skin in between — and the human eye is very bad at subtracting the gaps.

This is where the overestimate is manufactured. Someone with plaques on both elbows, both knees and the scalp will describe their arms and legs as affected, and the rule of nines will duly assign whole limbs. But six palm-sized plaques is six percent, not the thirty-six percent that four limbs would imply. The disease feels total because you are aware of it constantly and can see it in every mirror. Area is not the same measure as attention.

The discipline that fixes it is unglamorous: count handprints of involved skin, region by region, adding as you go — not handprints of the limbs those patches happen to sit on. Work through a fixed order so nothing is double-counted or forgotten: head and neck, each arm, front of trunk, back of trunk, each leg. If a plaque is smaller than your hand, estimate it as a fraction of one and keep a running tally.

Done properly this takes about three minutes and produces a number that will usually surprise the person doing it — because it is smaller than they expected, and because it is the first time they have measured rather than felt.

The thresholds, and how much rides on which side you land

The US convention divides at 3% and 10%: under 3% of surface area is mild, 3–10% moderate, above 10% severe. The European treatment-goals consensus uses what is often called the rule of tens — moderate-to-severe disease when body surface area exceeds 10, or PASI exceeds 10, or the dermatology life quality index exceeds 10. Different lines, same purpose: to mark the point at which treating the surface stops being a sensible plan and systemic therapy comes into the conversation.

Now put the estimation error next to those numbers. Someone with genuine 4% involvement who reports 15% has moved themselves from "a topical regimen used properly should handle this" to "we should discuss a systemic agent" — a conversation involving blood monitoring, drug interactions and real risk, opened on the basis of a mis-measurement. Run it the other way and someone with 12% who under-reports to 6% may fail an eligibility criterion for the treatment that would actually change their life, or lose an insurance argument they should have won. The question of ↗when it's time to consider a biologic is answered partly by this number, and ↗getting one approved often turns on it entirely.

The honest limitation is that these thresholds are crude on purpose. A recent analysis argued directly that commonly used clinical cut-offs fail to convey patient impact — and the counterexample everybody in the field knows is location. Disease on the palms, soles, face, scalp or genitals can be disabling at a surface area that rounds to nothing. Two percent on the soles of the feet can stop you working. Two percent on your back is a nuisance. A guideline that treats those as equivalent is wrong, which is why area is scored alongside a global assessment rather than instead of it — the logic behind the combined PGA and BSA product used in modern trials.

Where surface area meets the tube

The second thing BSA controls is quantity, and this is where the abstraction becomes a bathroom-cabinet fact.

The fingertip unit — the ribbon of ointment squeezed from a standard nozzle along the last segment of an adult index finger — weighs roughly half a gram and covers about 286 square centimetres of skin. That measure has anchored dermatology dosing since 1991, and the published per-region tables follow from it: two and a half units for face and neck, nearly seven for the front of the trunk, close to six for a leg. A whole-body application lands somewhere around forty units.

Do the multiplication and whole-body treatment becomes a tub-scale exercise rather than a tube-scale one. Which produces the single most useful diagnostic question in topical therapy: how long is your cream lasting? A prescription tube that has survived three months of daily whole-body use was not applied. Under-dosing is at least as common a cause of treatment failure as any pharmacological problem, and it is routinely misread by everyone involved as the drug not working.

This is also why the moisturiser layer of an eczema or psoriasis regimen is bought in the largest format available. A tub like CeraVe Moisturizing Cream or Cetaphil Moisturizing Cream is sized for the arithmetic; a boutique jar is not, and rationing an emollient defeats the entire point of prescribing one. For flare-prone skin, an oat-based option such as Aveeno Eczema Therapy Moisturizing Cream or a keratolytic-led one like CeraVe Psoriasis Moisturizing Cream does the same job with a targeted formula, and Aquaphor Healing Ointment covers the small, stubborn, fissured areas where an ointment beats a cream. The Fingertip Unit calculator converts your own affected regions into grams per application and tells you how long a given tube should honestly last.

One detail worth stating plainly: those FTU tables were derived for medicated topicals, where the dose has a therapeutic meaning. Emollient use is generally more generous, not less.

Paint the map, don't guess the number

The practical upgrade is to stop producing a percentage from intuition and start producing one from a map.

Before an appointment, work through the regions in a fixed order and record what is involved rather than what is affected in principle. Photograph the areas in consistent light so the next comparison is like-for-like. Then run the numbers through the BSA calculator rather than doing the arithmetic in your head under time pressure, and use the combined PGA and BSA tool if you want the composite figure that trials and prescribing decisions increasingly use. Bring the number and the photographs. A dermatologist given "about eight percent, mostly extensor surfaces, plus both soles" is having an entirely different consultation from one given "it's everywhere."

Then do it again in six weeks. The single measurement matters less than the trend, and the trend is the only thing that can tell you whether a treatment is working or whether your impression of it is being driven by how the worst patch looked this morning. ↗The psoriasis pathway and ↗the eczema pathway both escalate on exactly this kind of evidence, and both are much easier to navigate when you arrive holding a measurement instead of an adjective.

The uncomfortable part of all this is that the correction usually runs downward. Most people who measure carefully discover they have less disease than they believed — which is not the reassurance it sounds like, because their suffering was never a claim about area. It's simply that the number decides which treatments are on the table, and a number produced by feeling rather than counting will put the wrong ones there.